设计和实施试验以可靠地评估艾滋病预防干预措施。

Thomas R Fleming, Victor DeGruttola, Deborah Donnell
{"title":"设计和实施试验以可靠地评估艾滋病预防干预措施。","authors":"Thomas R Fleming,&nbsp;Victor DeGruttola,&nbsp;Deborah Donnell","doi":"10.1515/scid-2019-0001","DOIUrl":null,"url":null,"abstract":"<p><p>While much has been achieved, much remains to be accomplished in the science of preventing the spread of HIV infection. Clinical trials that are properly designed, conducted and analyzed are of integral importance in the pursuit of reliable insights about HIV prevention. As we build on previous scientific breakthroughs, there will be an increasing need for clinical trials to be designed to efficiently achieve insights without compromising their reliability and generalizability. Key design features should continue to include: 1) the use of randomization and evidence-based controls, 2) specifying the use of intention-to-treat analyses to preserve the integrity of randomization and to increase interpretability of results, 3) obtaining direct assessments of effects on clinical endpoints such as the risk of HIV infection, 4) using either superiority designs or non-inferiority designs with rigorous non-inferiority margins, and 5) enhancing generalizability through the choice of a relative risk rather than risk difference metric. When interventions have complementary and potentially synergistic effects, factorial designs should be considered to increase efficiency as well as to obtain clinically important insights about interaction and the contribution of component interventions to the efficacy and safety of combination regimens. Key trial conduct issues include timely enrollment of participants at high HIV risk recruited from populations with high viral burden, obtaining 'best real-world achievable' levels of adherence to the interventions being assessed and ensuring high levels of retention. High quality of trial conduct occurs through active rather than passive monitoring, using pre-specified targeted levels of performance with defined methods to achieve those targets. During trial conduct, active monitoring of the performance standards not only holds the trial leaders accountable but also can assist in the development and implementation of creative alternative approaches to increase the quality of trial conduct. Designing, conducting and analyzing HIV prevention trials with the quality needed to obtain reliable insights is an ethical as well as scientific imperative.</p>","PeriodicalId":74867,"journal":{"name":"Statistical communications in infectious diseases","volume":"11 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1515/scid-2019-0001","citationCount":"1","resultStr":"{\"title\":\"Designing & Conducting Trials To Reliably Evaluate HIV Prevention Interventions.\",\"authors\":\"Thomas R Fleming,&nbsp;Victor DeGruttola,&nbsp;Deborah Donnell\",\"doi\":\"10.1515/scid-2019-0001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>While much has been achieved, much remains to be accomplished in the science of preventing the spread of HIV infection. Clinical trials that are properly designed, conducted and analyzed are of integral importance in the pursuit of reliable insights about HIV prevention. As we build on previous scientific breakthroughs, there will be an increasing need for clinical trials to be designed to efficiently achieve insights without compromising their reliability and generalizability. Key design features should continue to include: 1) the use of randomization and evidence-based controls, 2) specifying the use of intention-to-treat analyses to preserve the integrity of randomization and to increase interpretability of results, 3) obtaining direct assessments of effects on clinical endpoints such as the risk of HIV infection, 4) using either superiority designs or non-inferiority designs with rigorous non-inferiority margins, and 5) enhancing generalizability through the choice of a relative risk rather than risk difference metric. When interventions have complementary and potentially synergistic effects, factorial designs should be considered to increase efficiency as well as to obtain clinically important insights about interaction and the contribution of component interventions to the efficacy and safety of combination regimens. Key trial conduct issues include timely enrollment of participants at high HIV risk recruited from populations with high viral burden, obtaining 'best real-world achievable' levels of adherence to the interventions being assessed and ensuring high levels of retention. High quality of trial conduct occurs through active rather than passive monitoring, using pre-specified targeted levels of performance with defined methods to achieve those targets. During trial conduct, active monitoring of the performance standards not only holds the trial leaders accountable but also can assist in the development and implementation of creative alternative approaches to increase the quality of trial conduct. Designing, conducting and analyzing HIV prevention trials with the quality needed to obtain reliable insights is an ethical as well as scientific imperative.</p>\",\"PeriodicalId\":74867,\"journal\":{\"name\":\"Statistical communications in infectious diseases\",\"volume\":\"11 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1515/scid-2019-0001\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Statistical communications in infectious diseases\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1515/scid-2019-0001\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2019/7/18 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Statistical communications in infectious diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1515/scid-2019-0001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2019/7/18 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

摘要

虽然已经取得了很大成就,但在预防艾滋病毒感染传播的科学方面仍有许多工作要做。正确设计、进行和分析的临床试验对于寻求有关艾滋病毒预防的可靠见解具有不可分割的重要性。随着我们在以往科学突破的基础上继续发展,我们将越来越需要设计临床试验,以便在不损害其可靠性和普遍性的情况下有效地获得见解。主要的设计特征应继续包括:1)使用随机化和循证对照,2)指定使用意向治疗分析以保持随机化的完整性并增加结果的可解释性,3)对临床终点(如HIV感染风险)的影响进行直接评估,4)使用具有严格非劣效边际的优势设计或非劣效设计。5)通过选择相对风险而不是风险差异度量来增强概括性。当干预措施具有互补和潜在的协同作用时,应考虑析因设计,以提高效率,并获得有关相互作用和组分干预措施对联合方案的有效性和安全性的贡献的临床重要见解。关键的试验行为问题包括及时从病毒负担高的人群中招募艾滋病毒高风险的参与者,获得对正在评估的干预措施的“最佳现实世界可实现”的坚持程度,并确保高水平的保留。高质量的试验行为是通过主动监测而不是被动监测来实现的,使用预先规定的目标绩效水平和确定的方法来实现这些目标。在审判过程中,积极监测执行标准不仅使审判负责人承担责任,而且有助于制定和实施创造性的替代方法,以提高审判的质量。设计、开展和分析具有获得可靠见解所需质量的艾滋病毒预防试验是伦理和科学上的当务之急。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Designing & Conducting Trials To Reliably Evaluate HIV Prevention Interventions.

Designing & Conducting Trials To Reliably Evaluate HIV Prevention Interventions.

Designing & Conducting Trials To Reliably Evaluate HIV Prevention Interventions.

Designing & Conducting Trials To Reliably Evaluate HIV Prevention Interventions.

While much has been achieved, much remains to be accomplished in the science of preventing the spread of HIV infection. Clinical trials that are properly designed, conducted and analyzed are of integral importance in the pursuit of reliable insights about HIV prevention. As we build on previous scientific breakthroughs, there will be an increasing need for clinical trials to be designed to efficiently achieve insights without compromising their reliability and generalizability. Key design features should continue to include: 1) the use of randomization and evidence-based controls, 2) specifying the use of intention-to-treat analyses to preserve the integrity of randomization and to increase interpretability of results, 3) obtaining direct assessments of effects on clinical endpoints such as the risk of HIV infection, 4) using either superiority designs or non-inferiority designs with rigorous non-inferiority margins, and 5) enhancing generalizability through the choice of a relative risk rather than risk difference metric. When interventions have complementary and potentially synergistic effects, factorial designs should be considered to increase efficiency as well as to obtain clinically important insights about interaction and the contribution of component interventions to the efficacy and safety of combination regimens. Key trial conduct issues include timely enrollment of participants at high HIV risk recruited from populations with high viral burden, obtaining 'best real-world achievable' levels of adherence to the interventions being assessed and ensuring high levels of retention. High quality of trial conduct occurs through active rather than passive monitoring, using pre-specified targeted levels of performance with defined methods to achieve those targets. During trial conduct, active monitoring of the performance standards not only holds the trial leaders accountable but also can assist in the development and implementation of creative alternative approaches to increase the quality of trial conduct. Designing, conducting and analyzing HIV prevention trials with the quality needed to obtain reliable insights is an ethical as well as scientific imperative.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信